首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1881251

肿瘤单株抗体合作与授权协议（2016-2025）

Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 350+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

"肿瘤单株抗体合作与授权协议" 全面深入分析了全球领先的生物製药公司签署的肿瘤单株抗体协议，并提供前所未有的资讯取得管道。

这份经过全面修订和更新的报告详细介绍了2016年至2025年间的肿瘤单株抗体协议。

本报告深入分析了企业签订肿瘤单株抗体协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，逐步推进到成果的商业化。

本报告涵盖合作、开发、研究和授权。

本报告包含自 2016 年以来宣布的 632 项肿瘤单株抗体交易的完整清单。该报告还提供了指向实际癌症单株抗体合作交易在线记录的链接，包括可用的财务条款以及交易双方披露的条款。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了癌症单株抗体交易。

第一章概述了本报告。

第二章概述了自 2016 年以来癌症单株抗体交易的趋势。

第三章概述了自 2016 年以来主要的癌症单株抗体交易，并依交易额列出。

第四章提供了最活跃的 25 家癌症单株抗体交易撮合者的完整名单，并附有简要概述，随后提供了癌症单株抗体交易的完整列表以及公开的合约文件。

第五章对自 2016 年 1 月以来已完成或宣布的癌症单株抗体交易进行了全面深入的回顾，涵盖了合约文件公开可取得的交易。

第六章对自2016年1月以来已达成或宣布的癌症单株抗体合作协议进行了全面深入的回顾。本章以癌症单株抗体技术的具体类型进行组织。

本报告还包含大量表格和图表，展示了自2016年以来癌症单株抗体交易的趋势和动态。

此外，我们还提供了一个全面的合约目录，依公司名称（A-Z）、合约类型和治疗标靶进行分类。每个合约标题都透过网路连结指向线上合约记录，并在可用的情况下指向合约文件，以便根据需要轻鬆查阅每个合约文件。

主要优势

本报告 "癌症单株抗体研究合作与授权协议" 为读者提供以下主要优势：

了解自 2016 年以来的交易趋势
浏览癌症单株抗体合作与授权协议
基准分析 - 确定交易市场价值
财务条款 - 预付款、里程碑付款、特许权使用费
依公司（A-Z）、协议类型和治疗领域分类的合约目录
以价值排名的主要交易
最活跃的交易撮合者
识别每笔交易的资产和条款
存取合约文件 - 深入了解交易结构
尽职调查 - 评估拟议交易条款对合作公司的适用性
节省数百小时的研究时间

范围

本报告 "癌症单株抗体合作与授权协议" 旨在帮助读者深入了解全球领先生物製药公司之间癌症单株抗体相关协议的趋势和结构。

本报告内容： "肿瘤单株抗体合作与授权协议"

生物製药产业肿瘤单株抗体交易趋势
製药和生物技术公司肿瘤单株抗体合约记录目录
依价值排名的主要肿瘤单株抗体合约
最活跃的肿瘤单株抗体授权协议公司
"肿瘤单株抗体合作与许可协议" 提供对现有交易记录（包括合约文件）的全面存取。

分析合约内容有助于对以下方面进行尽职调查：

合约具体授予或选择哪些权利？
合约实际授予合作伙伴哪些权利？
授予了哪些排他性权利？
交易的付款结构是什么？
销售和付款如何审计？
合约期限是多久？
合约的关键条款是如何定义的？
智慧财产权（IPR）如何处理归属于谁？
谁负责商业化？
谁负责开发、供应和生产？
如何管理保密性和资讯揭露？
如何解决争议？
合约在什么情况下可以终止？
如果所有权发生变更，会发生什么事？
如何约定转让许可和分包条款？
贵公司需要哪些标准条款？
哪些标准条款会因交易对手和交易类型而异？
贵公司必须在哪个司法管辖区内履行合约？

引言
历年癌症单株抗体交易状况
最活跃的癌症单株抗体交易商
依交易类型划分的癌症单株抗体交易
依治疗领域划分的癌症单株抗体交易
依行业划分的癌症单株抗体交易
癌症单株抗体交易条款
- 癌症单株抗体交易总额
- 癌症单株抗体交易预付款
- 癌症单株抗体交易里程碑付款
- 特许权使用费癌症单株抗体价格

第三章 - 主要癌症单株抗体交易

引言
以价值排名的顶级癌症单株抗体交易

第四章 - 最活跃的癌症单株抗体交易者

引言
最活跃的癌症单株抗体交易商
最活跃的癌症单株抗体交易商公司简介

第五章 - 癌症单株抗体合约交易目录

引言
癌症单株抗体合约交易目录

第六章 - 依技术分类的癌症单株抗体交易

交易目录
癌症交易目录单株抗体交易（依公司、亚利桑那州分类）
交易目录 - 依交易类型分类的癌症单株抗体交易
交易目录 - 依治疗领域分类的肿瘤单株抗体交易
交易类型定义
关于研究公司
当前合作伙伴关係
当前协议
依目前合作伙伴关係分类的近期报告标题

简介目录

Product Code: CP22012

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available including links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer monoclonal antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer monoclonal antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer monoclonal antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse cancer monoclonal antibody collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Cancer Monoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer monoclonal antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Monoclonal Antibody Collaboration and Licensing Deals includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry
Directory of cancer monoclonal antibody deal records covering pharmaceutical and biotechnology
The leading cancer monoclonal antibody deals by value
Most active cancer monoclonal antibody licensing dealmakers
Cancer Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

2.1. Introduction
2.2. Cancer monoclonal antibody deals over the years
2.3. Most active cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody deals by deal type
2.5. Cancer monoclonal antibody deals by therapy area
2.6. Cancer monoclonal antibody deals by industry sector
2.7. Deal terms for cancer monoclonal antibody deals
- 2.7.1 Cancer monoclonal antibody deals headline values
- 2.7.2 Cancer monoclonal antibody deal upfront payments
- 2.7.3 Cancer monoclonal antibody deal milestone payments
- 2.7.4 Cancer monoclonal antibody royalty rates